HMMJ-U:CA:TSX-Horizons Marijuana Life Sciences Index ETF (USD)

ETF | Others |

Last Closing

CAD 7.56

Change

0.00 (0.00)%

Market Cap

CAD 0.09B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.22 (-0.76%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 5.37B
XEQT:CA iShares Core Equity Portfolio

-0.20 (-0.62%)

CAD 4.78B
PHYS-U:CA Sprott Physical Gold Trust

+0.26 (+1.28%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

-0.29 (-0.80%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

N/A

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.26 (+1.06%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.08 (-0.75%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

N/A

CAD 2.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.02 (+0.04%)

CAD 2.53B

ETFs Containing HMMJ-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.15% 42% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.15% 41% F 37% F
Trailing 12 Months  
Capital Gain 14.55% 40% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.55% 39% F 36% F
Trailing 5 Years  
Capital Gain -16.09% 5% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.09% 5% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 21.68% N/A N/A 87% B+
Dividend Return 21.70% N/A N/A 86% B+
Total Return 0.02% N/A N/A 4% F
Risk Return Profile  
Volatility (Standard Deviation) 61.15% N/A N/A 14% F
Risk Adjusted Return 35.49% N/A N/A 54% F
Market Capitalization 0.09B 62% D 33% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike